CytoMed Therapeutics Limited (GDTC)
GDTC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1873093/000149315226013813/0001493152-26-013813-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GDTC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Singapore |
| IPO year | 2023 |
| SEC CIK | 0001873093 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Singapore |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $252K |
| Net income | -$3.1M |
| Operating income | Not in SEC XBRL data |
| Net margin | -1227.1% |
| Operating margin | Operating income not reported |
| Revenue growth | +395.9% |
| Cash | $1.6M |
| Total assets | $6.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 36.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "At present time, we manufacture limited quantities of cells for researchers and institutions on a non-profit, cost recovery basis for the purpose of research. 1 We have incurred losses since our incorporation and we expect to incur significant losses for the foreseeable future, which raise substantial doubt on our ability to continue as a going concern." | 20-F 2026-03-31 |
| Cash and burn | $1.6M cash; operating cash flow -$719K a quarter. | Report 2025-12-31 |
| Shares outstanding | 11,828,435 (2025-12-31); 11,540,000 a year earlier; 11,529,328 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WWC, P.C., San Mateo, California, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $429K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $252K | -$3.1M | -$2.9M | $1.6M | $318K | $252K | 20-F 2026-03-31 |
| FY 2024 2024-12-31 | $51K | -$1.8M | -$2.0M | $3.7M | $316K | $51K | 20-F 2025-04-28 |
| FY 2023 2023-12-31 | Not filed | -$3.1M | -$2.6M | $4.6M | $335K | Needs four quarters | 20-F 2024-04-22 |
| FY 2022 2022-12-31 | Not filed | -$2.3M | -$1.0M | $1.2M | $600K | Needs four quarters | 20-F 2023-05-01 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-08-18 |
| Latest annual report | 20-F | 2026-03-31 |
| Latest quarterly / interim | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 132 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.5% |
| 1 month | -4.7% |
| 3 months | -1.9% |
| Year to date | -37.9% |
| 1 year | -56.8% |
| From 52-week high | -58.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BFRG | Bullfrog AI Holdings Inc. | $0.4878 | -9.92% | $9.0M |
| LEXX | Lexaria Bioscience Corp. | $4.41 | -0.68% | $9.3M |
| PHIO | Phio Pharmaceuticals Corp. | $0.7522 | -2.44% | $9.0M |
| VTGN | Vistagen Therapeutics Inc. | $0.1843 | +2.11% | $8.5M |
| AEON | AEON Biopharma Inc. | $0.1407 | -8.04% | $10.1M |
| CLRB | Cellectar Biosciences Inc. | $1.01 | -11.40% | $10.1M |
| CALC | CalciMedica Inc. | $1.19 | -1.65% | $8.2M |
| BFRI | Biofrontera Inc. | $0.5700 | -18.58% | $10.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier